Microcore Biotechnology: Sitagliptin Metformin Sustained-Release Tablets received the drug clinical trial approval notification.

On March 16th, Weix Microorganism announced that the company and its wholly-owned subsidiary, Chengdu Weix Pharmaceutical Co., Ltd., recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, allowing the company's product Sitagliptin Metformin Sustained-Release Tablets to conduct clinical trials. Sitagliptin Metformin Sustained-Release Tablets is a fixed-dose combination sustained-release formulation independently developed by the company, which treats type 2 diabetes through different mechanisms of action, allowing patients to achieve better blood sugar control.